Programs

GHA offers support for individuals and families. These range from support groups to educational programs, emergency financial assistance, and college scholarships. For more information, contact info@gatewayhemophilia.org

Camp Notaclotamongus

Women’s Group

Men’s Group

Teen Group

Financial Assistance

The Helping Hands Program exists for the sole purpose of providing emergency financial assistance to those persons who have been physically, emotionally and financially affected by a blood coagulation disorder.

The mission of GHA’s Scholarship Program is to sponsor scholarships to aid and encourage post high-school education for students with hemophilia, vWd, or a related bleeding disorder.

For more information on these programs, follow the links above.

Resources

To view a listing of patient assistance programs and other financial assistance resources click here.

To view a listing of MO vocational rehabilitation programs click here or for IL vocational rehabilitation programs click here.

Sign Up For Our Newsletter

Upcoming Events

12/07/2023

Join us to learn more about switching it up with ALTUVIIIO

The Train Shed

201 S 18th St, St. Louis, MO 63103

Start Time: 6:15 p.m.

Learn more about factor activity levels and the benefits and safety of a once-weekly treatment. This educational program provides an interactive, engaging experience sponsored by Sanofi. A Community Relations and Education (CoRe) Manager, Kyrie Smith will provide an understanding about the role of factor activity levels and information about what this treatment option could mean for your management plan. Reply by 12/4 to carly@gatewayhemophilia.org.Parking will be validated.

Also hear from David who will share his story and experience on Altuviiio.

Switch it up with ALTUVIIIO

ALTUVIIIO and Sanofi are trademarks of Sanofi or an affiliate.
INDICATION: ALTUVIIIOTM [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

12/20/2023